文献速递乳房整形与再造美容整形

乳房缩小术标本的组织学评估是否值得?

Is Histological Evaluation of Reduction Mammaplasty Specimens Worthwhile?
PubMed 文献 · Aesthet Surg J · 2019-01-01

作者认为乳房缩小术是检出增殖性病变和隐匿性癌的好机会,建议所有标本送病理检查。

要点

  • 乳房缩小术标本可检出隐匿性乳腺癌(0.56%)和非典型导管增生(0.71%)。
  • 纤维囊性变是最常见病变,占81.3%。
  • 建议无论标本重量,所有乳腺组织均送病理检查。

核心结论

  • 乳房缩小术是检出增殖性病变和隐匿性乳腺癌的良好机会,应重视组织病理学评估。

主要发现

  • 非典型导管增生5例(0.71%),无小叶原位癌;隐匿性乳腺癌4例(0.56%),良性叶状肿瘤1例(0.14%)。

关键数值与推荐

  • 建议所有乳腺组织均应送病理检查,无论标本重量。
  • 即使医保不覆盖费用,也应告知患者该过程的重要性。

临床怎么用

  • 乳房缩小术中应常规送检全部切除组织,并术前告知患者病理评估的意义。

局限性

  • 单中心回顾性设计,仅代表土耳其爱琴海地区人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Reduction mammaplasty (RM) is one of the most common plastic surgery procedures. Despite its cost, the total number of RM procedures continues to increase every year. OBJECTIVES: The purpose of this study is to review the prevalence of benign and malignant breast lesions among women who live in the Aegean region of Turkey, based on our university hospital's records and to compare our results with those in the literature. METHODS: Seven hundred and thirty-three consecutive female patients who underwent RM between January 2003 and January 2017 in the Department of Plastic, Reconstructive, and Aesthetic Surgery were included in this study. RESULTS: One hundred and sixty-five patients (23.4%) had preoperative breast imaging results. According to the Breast Imaging Reporting and Data System (BIRADS), most of these patients had BI-RADS-2 and BIRADS-1 findings (41.21% and 40%, respectively). Fibrocystic changes were the most common lesions (81.3%). Sixty-eight patients (9.6%) had normal breast tissue on the right side and 34 patients (4.8%) had the same on the left side. Five patients (0.71%) had atypical ductal hyperplasia and no atypical lobular carcinoma. Four patients (0.56%) had occult breast cancer and one patient (0.14%) had benign phyllodes tumor. CONCLUSIONS: RM is a good opportunity to detect proliferative lesions and occult breast cancer. While meeting the patient's aesthetic desires, the plastic surgeon should consider for histopathological evaluation. We suggest that every part of the breast tissue should be sent to pathological examination regardless of the weight of the specimen. Even if health insurance does not cover its cost, patients should be informed about the importance of this process.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Demirdover C, Geyik A, Vayvada H, et al. Is Histological Evaluation of Reduction Mammaplasty Specimens Worthwhile? Aesthet Surg J. 2019. PMID: 30371739. doi:10.1093/asj/sjy295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。